Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Besponsa + Rituximab in B-cell NHL
NCT00299494Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2006
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of inotuzumab ozogamicin in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Transformed Follicular Lymphoma (tFL), sponsored by Pfizer. Started May 2006; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)Transformed Follicular Lymphoma (tFL)
Beyond the preview
Go deeper on NCT00299494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00299494.